Objective: To compare medroxyprogesterone acetate (MPA) concentrations between HIV-positive women on antiretroviral therapy (ART) and HIV-negative women initiating depot medroxyprogesterone (DMPA) injectable.
Study design: Secondary analysis of 28 HIV-positive women on non-nucleoside reverse transcriptase inhibitor-containing ART regimens and 10 HIV-negative women randomized to initiate DMPA in a clinical trial of progestin contraception in Malawi.
Results: MPA concentrations were significantly lower among HIV-positive women on ART, compared with HIV-negative women, at week 4 and week 13 (p=.03 for both), but not at day 3 or week 26 post-DMPA initiation.
Conclusions: Antiretroviral medications may affect MPA metabolism in HIV-positive African women.
Trial registration: ClinicalTrials.gov NCT02103660.
Keywords: Africa; Antiretroviral therapy; Depot medroxyprogesterone acetate; HIV.
Copyright © 2019 Elsevier Inc. All rights reserved.